Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

Dusheiko, Geoffrey; Main, Janice; Thomas, Howard; Reichard, Olle; Lee, Christine; Dhillon, Amar P.; Rassam, Suhra; Frydén, Aril; Reesink, H. W.; Bassendine, Margaret F.; Norkrans, Gunnar; Cuypers, Theo; Lelie, Nico; Telfer, Paul; Watson, John; Weegink, Christine J.; Sillikens, Peter; Weiland, Ola

doi:10.1016/s0168-8278(96)80225-x

Cited by 319 publications

(218 citation statements)

References 23 publications

Supporting

Mentioning

207

Contrasting

Unclassified

Order By: Relevance

“…However, it is important to note that despite the presence of high titer IFN-neutralizing antibodies in 1997, patient P#9 showed a transient elimination of HCV RNA and ALT normalization during a second course of IFN therapy, this time in combination with ribavirin. This might either reflect the direct anti-viral effect of ribavirin as shown previously with ribavirin monotherapies [Di Bisceglie et al, 1995;Dusheiko et al, 1996;Hoofnagle et al, 1996] or some remaining IFN-activity not neutralized by the antibodies. Unfortunately, no PBMCs were available from this period of time to retrospectively determine the IFN-a bioactivity in patient P#9.…”

Section: Discussionmentioning

confidence: 79%

Rapid and simple detection of IFN‐neutralizing antibodies in chronic hepatitis C non‐responsive to IFN‐α

Jorns

Holzinger

Thimme

et al. 2005

Journal of Medical Virology

View full text Add to dashboard Cite

Different mechanisms have been proposed for the failure of interferon (IFN) therapy in patients with chronic hepatitis C and multiple sclerosis, for example, the presence of IFN-neutralizing antibodies. In this study, a novel assay system based on the IFN-inducible Mx-promoter was used to detect IFN-neutralizing antibodies in sera of patients with chronic hepatitis C. To monitor IFN bioactivity in IFN-treated patients, a real-time RT-PCR for MxA gene expression in PBMCs was established. Using these two methods, patients with chronic hepatitis C virus (HCV) infection receiving IFN therapy and patients with treatment induced HCV clearance were monitored. Importantly, neutralizing anti-IFN antibodies were detected in the sera of 3 of 38 chronically HCVinfected patients who failed to respond to therapy but none in sera of patients who cleared HCV after IFN therapy. Interestingly, the presence of these antibodies correlated with the lack of MxA induction in PBMCs after initiation of IFN-a therapy. Retrospective analysis of one patient's sera revealed that the anti-IFN-a antibodies had already developed after the first of four unsuccessful IFN therapies, suggesting that neutralizing antibodies may have contributed to the failure of previous IFN treatments. In summary, a novel screening assay was established that may be helpful for testing IFN non-responders for the presence of clinically relevant anti-IFN-a antibodies and for selecting alternative IFN preparations not neutralized by these antibodies.

show abstract

Section: Discussionmentioning

confidence: 79%

Rapid and simple detection of IFN‐neutralizing antibodies in chronic hepatitis C non‐responsive to IFN‐α

Jorns

Holzinger

Thimme

et al. 2005

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Ribavirin alone does not appear to be effective (579,580). However, the combination of interferonalpha and ribavirin is superior to interferon alpha alone in inducing sustained remission from HCV in patients who have not previously been treated with interferon alpha (581)(582)(583)(584)(585)(586).…”

Section: The Evaluation Of Renal Transplant Candidates: Clinical Pracmentioning

confidence: 99%

“…* Six of 9 patients were initially treated daily for 2 weeks. increased, especially hemolytic anemia (580,583,584,587,592,596). Unfortunately, there are few studies examining ribavirin in patients with ESRD.…”

Section: The Evaluation Of Renal Transplant Candidates: Clinical Pracmentioning

confidence: 99%

The Evaluation of the Renal Transplant Candidates: Clinical Practice Guidelines

2001

American Journal of Transplantation

View full text Add to dashboard Cite

“…However, results from early ribavirin monotherapy trials in naïve and nonresponder patients were disappointing and indicated transient improvements in aminotransferases and necroinflammation only, without significant viral suppression or change in fibrosis scores. [7][8][9][10][11][12][13] In this issue, Hoofnagle et al at the National Institutes of Health have attempted to extend and further evaluate the role of ribavirin as maintenance therapy in patients that do not achieve virologic clearance after 24 weeks of standard combination therapy. In a well-designed study, 108 patients received at least 24 weeks of therapy.…”

mentioning

confidence: 99%

Ribavirin As Maintenance Therapy for Hepatitis C Patients: An Interim Peacekeeper?

et al. 2003

View full text Add to dashboard Cite

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

Cited by 319 publications

References 23 publications

Rapid and simple detection of IFN‐neutralizing antibodies in chronic hepatitis C non‐responsive to IFN‐α

Rapid and simple detection of IFN‐neutralizing antibodies in chronic hepatitis C non‐responsive to IFN‐α

The Evaluation of the Renal Transplant Candidates: Clinical Practice Guidelines

Ribavirin As Maintenance Therapy for Hepatitis C Patients: An Interim Peacekeeper?

Contact Info

Product

Resources

About